<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cardiac Pharmacology - PiCCO Online Manual</title>
    <link href="https://fonts.googleapis.com/css2?family=Lato:wght@400;700&family=Montserrat:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../CSS/main.css">
    <link rel="stylesheet" href="../CSS/print.css" media="print">
    <link rel="stylesheet" href="../CSS/cards.css">
</head>
<body>
    <div class="nav-overlay" id="nav-overlay"></div>
    <header class="main-header">
        <h1 class="site-title"><a href="../index.html" class="site-title"><span class="green-highlighted-oval-3d">PiCCO</span> - <span class="color-red">O</span>nline Manual</a></h1>
        <button class="menu-toggle" id="menu-toggle">‚ò∞</button>
    </header>

    <div class="wrapper container">
        <nav class="main-nav" id="main-nav">
            <h2>Sections</h2>
            <div class="search-container">
                <input type="text" id="searchInput" placeholder="Search sections..." aria-label="Search sections">
            </div>
            <ul>
                <li><a href="introduction.html">Introduction</a></li>
                <li><a href="principles.html">Principles</a></li>
                <li><a href="history.html">History</a></li>
                <li><a href="equipment.html">Equipment</a></li>
                <li><a href="calibration.html">Calibration</a></li>
                <li><a href="indications.html">Indications</a></li>
                <li><a href="contraindications.html">Contraindications</a></li>
                <li><a href="limitations.html">Limitations</a></li>
                <li><a href="pediatric.html">Pediatric considerations</a></li>
                <li><a href="preload.html">Preload</a></li>
                <li><a href="contractility.html">Contractility</a></li>
                <li><a href="lungwater.html">Lung water</a></li>
                <li><a href="afterload.html">Afterload</a></li>
                <li><a href="dynamic.html">Dynamic parameters</a></li>
                <li><a href="derived.html">Derived parameters</a></li>
                <li><a href="algorithms.html">Algorithms</a></li>
                <li><a href="cases.html">Clinical cases</a></li>
                <li><a href="errors.html">Errors</a></li>
                <li><a href="physiology.html">Physiology</a></li>
                <li><a href="reference.html">Reference</a></li>
                <li><a href="faq.html">FAQ</a></li>
                <li><a href="visualizations.html">Visualizations</a></li>
                <li><a href="periodic-table.html">Periodic Table</a></li>
                <li><a href="pharmacology.html" class="active">Pharmacology</a></li>
                <li><a href="about.html">About</a></li>
                <li><a href="simulation.html">Quiz</a></li>
            </ul>
        </nav>

        <main class="main-content">
            <h2 class="page-title">Cardiac Pharmacology Reference</h2>
            
            <div class="card-table" id="pharmaTable"></div>
            <div class="tooltip" id="tooltip"></div>
        </main>
    </div>

    <footer class="main-footer">
        <div class="container">
            <p>¬© 2025 <span class="green-highlighted-oval-3d">PiCCO</span> Online Manual</p>
        </div>
    </footer>
    
    <button class="theme-switcher" id="theme-switcher" aria-label="Toggle theme">
        <span class="icon-sun">‚òÄÔ∏è</span>
        <span class="icon-moon" style="display: none;">üåô</span>
    </button>

    <script>
        const drugs = {
            norepinephrine: {
                category: 'Vasopressor<br>Catecholamine',
                name: 'Norepinephrine',
                symbol: 'Nori',
                receptor: 'Œ±1 > Œ≤1',
                dose: 'Adult: 0.01-3 Œºg/kg/min<br>Peds: 0.05-2 Œºg/kg/min',
                class: 'norepinephrine',
                mechanism: 'Potent Œ±1-adrenergic agonist (vasoconstriction) with moderate Œ≤1 activity (inotropy). Increases SVR and MAP with minimal effect on HR. Acts on vascular Œ±1 receptors causing arteriolar and venous constriction.',
                indications: 'First-line vasopressor for septic shock, cardiogenic shock with low SVR, neurogenic shock, anaphylaxis. Preferred in distributive shock states.',
                contraindications: 'Hypovolemia without adequate fluid resuscitation (relative). Avoid in pheochromocytoma, mesenteric/peripheral vascular thrombosis (relative).',
                sideeffects: 'Tissue necrosis if extravasation, bradycardia (reflex), arrhythmias, digital/limb ischemia at high doses, increased myocardial oxygen demand.',
                remarks: 'GOLD STANDARD for septic shock. Requires central line (can use peripheral temporarily). Monitor tissue perfusion (lactate, ScvO‚ÇÇ). Titrate to MAP ‚â•65 mmHg. Can cause reflex bradycardia via baroreceptor activation. DO NOT mix with alkaline solutions.'
            },
            epinephrine: {
                category: 'Vasopressor<br>Inotrope',
                name: 'Epinephrine',
                symbol: 'Epi',
                receptor: 'Œ±1, Œ≤1, Œ≤2',
                dose: 'Adult: 0.01-0.5 Œºg/kg/min<br>Peds: 0.01-1 Œºg/kg/min<br>Bolus: 1 mg IV (arrest)',
                class: 'epinephrine',
                mechanism: 'Non-selective Œ± and Œ≤ agonist. Low doses (<0.05): Œ≤1/Œ≤2 effects (inotropy, chronotropy, bronchodilation). High doses: Œ±1 predominates (vasoconstriction). Increases CO, HR, SVR, myocardial contractility.',
                indications: 'Anaphylaxis (IM 0.3-0.5mg), cardiac arrest, severe bradycardia, refractory shock not responding to norepinephrine, post-cardiac surgery low CO state, Œ≤-blocker overdose.',
                contraindications: 'No absolute contraindications in life-threatening situations. Relative: uncontrolled tachyarrhythmias, coronary insufficiency.',
                sideeffects: 'Tachycardia, arrhythmias (VT/VF), myocardial ischemia, hyperglycemia, hypokalemia, lactic acidosis (Œ≤2-mediated), pulmonary edema, tissue necrosis if extravasation.',
                remarks: 'HIGHLY arrhythmogenic - continuous ECG monitoring essential. Causes significant increase in myocardial O‚ÇÇ consumption. May worsen lactate due to Œ≤2-mediated aerobic glycolysis (type B lactic acidosis) - do not interpret elevated lactate as worsening shock. Use with extreme caution in coronary disease. First-line for anaphylaxis (IM route).'
            },
            vasopressin: {
                category: 'Vasopressor<br>ADH analog',
                name: 'Vasopressin',
                symbol: 'Vaso',
                receptor: 'V1, V2',
                dose: 'Adult: 0.01-0.04 U/min<br>Peds: 0.0003-0.002 U/kg/min',
                class: 'vasopressin',
                mechanism: 'V1 receptor agonist ‚Üí vascular smooth muscle contraction. V2 receptor ‚Üí renal water reabsorption. Non-adrenergic vasoconstrictor. Maintains vasomotor tone in catecholamine-refractory shock (restores vascular sensitivity).',
                indications: 'Septic shock refractory to norepinephrine, vasodilatory shock post-cardiac surgery, cardiac arrest (alternative to epinephrine), diabetes insipidus, GI bleeding (terlipressin preferred).',
                contraindications: 'Coronary artery disease (relative - may cause coronary vasoconstriction), advanced vascular disease. No dose titration - fixed dose only.',
                sideeffects: 'Digital/splanchnic ischemia, hyponatremia (water retention), coronary vasoconstriction, decreased CO, bradycardia, arrhythmias, skin necrosis, decreased platelet count.',
                remarks: 'Used as ADJUNCT to norepinephrine, NOT monotherapy. FIXED DOSE (0.03-0.04 U/min in adults) - do not titrate. May allow reduction of catecholamine doses (catecholamine-sparing). Particularly useful in septic shock with relative vasopressin deficiency. Does NOT increase HR (unlike catecholamines). May worsen cardiac output in cardiogenic shock. Monitor for mesenteric ischemia.'
            },
            phenylephrine: {
                category: 'Vasopressor<br>Pure Œ±-agonist',
                name: 'Phenylephrine',
                symbol: 'Neo',
                receptor: 'Œ±1',
                dose: 'Adult: 0.5-3 Œºg/kg/min<br>Bolus: 50-200 Œºg<br>Peds: 0.5-3 Œºg/kg/min',
                class: 'phenylephrine',
                mechanism: 'Pure Œ±1-adrenergic agonist. Increases SVR via arterial vasoconstriction. NO direct cardiac effects (no Œ≤ activity). May decrease CO via reflex bradycardia and increased afterload.',
                indications: 'Hypotension during anesthesia, temporary support during norepinephrine preparation, supraventricular tachycardia (reflex bradycardia), patients with tachyarrhythmias where Œ≤-agonists undesirable.',
                contraindications: 'Severe hypertension, ventricular tachycardia. Use cautiously in coronary disease, heart failure (increases afterload ‚Üí may worsen CO).',
                sideeffects: 'Reflex bradycardia, decreased CO, increased afterload, headache, hypertension, tissue necrosis with extravasation.',
                remarks: 'PURE vasoconstrictor - NO inotropic support. May DECREASE cardiac output due to increased afterload. Useful for brief blood pressure support or in tachycardic patients. Can cause significant bradycardia (baroreceptor reflex). NOT ideal for prolonged shock support - norepinephrine preferred. Good for anesthesia-induced hypotension (bolus dosing).'
            },
            dopamine: {
                category: 'Vasopressor<br>Inotrope',
                name: 'Dopamine',
                symbol: 'Dopa',
                receptor: 'D, Œ≤, Œ±',
                dose: 'Adult: 2-20 Œºg/kg/min<br>Peds: 2-20 Œºg/kg/min',
                class: 'dopamine',
                mechanism: 'Dose-dependent effects. Low (2-5): D1/D2 receptors ‚Üí renal/splanchnic vasodilation. Medium (5-10): Œ≤1 ‚Üí inotropy/chronotropy. High (>10): Œ±1 ‚Üí vasoconstriction. Precursor to norepinephrine.',
                indications: 'Bradycardia with hypotension (alternative to atropine/pacing), cardiogenic shock (historically - dobutamine now preferred), shock in bradycardic patients.',
                contraindications: 'Pheochromocytoma, uncorrected tachyarrhythmias, hypovolemia. Avoid in tachydysrhythmias.',
                sideeffects: 'Tachycardia (dose-limiting), arrhythmias (VT/VF), myocardial ischemia, increased pulmonary shunting, tissue necrosis, nausea/vomiting.',
                remarks: 'LARGELY REPLACED by norepinephrine due to higher arrhythmia risk. "Renal-dose dopamine" (2-5 Œºg/kg/min) is NOT supported by evidence and NOT recommended. MORE arrhythmogenic than norepinephrine. May increase mortality in cardiogenic shock compared to norepinephrine. Useful in bradycardic shock. Unpredictable effects due to dose-dependent receptor activity.'
            },
            terlipressin: {
                category: 'Vasopressor<br>ADH analog',
                name: 'Terlipressin',
                symbol: 'Terli',
                receptor: 'V1',
                dose: 'Adult: 1-2 mg bolus q4-6h<br>Peds: Limited data',
                class: 'terlipressin',
                mechanism: 'Vasopressin analog, V1 receptor agonist. Prodrug converted to lysine-vasopressin. Longer half-life than vasopressin (4-6h vs 10-20min). Splanchnic vasoconstriction.',
                indications: 'Hepatorenal syndrome, variceal bleeding, septic shock (less common than vasopressin), catecholamine-refractory shock.',
                contraindications: 'Coronary artery disease, peripheral vascular disease, pregnancy.',
                sideeffects: 'Myocardial ischemia, arrhythmias, mesenteric ischemia, hyponatremia, skin necrosis, bradycardia.',
                remarks: 'PRIMARILY used for variceal bleeding and hepatorenal syndrome. Longer duration allows bolus dosing vs continuous infusion. Significant risk of ischemic complications. Less commonly used than vasopressin in general ICU settings. NOT available in all countries (not FDA approved in USA).'
            },
            dobutamine: {
                category: 'Inotrope<br>Œ≤-agonist',
                name: 'Dobutamine',
                symbol: 'Dobu',
                receptor: 'Œ≤1 > Œ≤2',
                dose: 'Adult: 2-20 Œºg/kg/min<br>Peds: 2-20 Œºg/kg/min',
                class: 'dobutamine',
                mechanism: 'Synthetic catecholamine. Primarily Œ≤1-agonist (inotropy, chronotropy) with mild Œ≤2 (vasodilation) and Œ±1 effects. Increases CO and SV. Decreases SVR and PCWP. Improves myocardial contractility.',
                indications: 'Cardiogenic shock, acute decompensated heart failure with low CO, stress testing (pharmacologic), right ventricular failure, weaning from cardiopulmonary bypass.',
                contraindications: 'Hypertrophic obstructive cardiomyopathy, aortic stenosis (severe), uncorrected hypovolemia, tachydysrhythmias, acute MI with hypotension.',
                sideeffects: 'Tachycardia, increased myocardial O‚ÇÇ demand, arrhythmias, hypotension (Œ≤2 vasodilation), myocardial ischemia, hypokalemia.',
                remarks: 'INOTROPE of choice for cardiogenic shock with adequate BP. May DECREASE blood pressure due to Œ≤2-mediated vasodilation - combine with vasopressor if hypotensive. Increases myocardial oxygen consumption - monitor for ischemia. Can worsen hypotension in severe shock - norepinephrine often added. Tachyphylaxis develops after 48-72h. NOT for distributive shock.'
            },
            milrinone: {
                category: 'Inotrope<br>PDE-3 inhibitor',
                name: 'Milrinone',
                symbol: 'Milri',
                receptor: 'PDE3i',
                dose: 'Adult: Load 50 Œºg/kg, then 0.375-0.75 Œºg/kg/min<br>Peds: 0.25-0.75 Œºg/kg/min',
                class: 'milrinone',
                mechanism: 'Phosphodiesterase-3 inhibitor ‚Üí increases cAMP. Positive inotropy (increased contractility) AND vasodilation (afterload reduction). Lusitropic effect (improved diastolic relaxation). Does NOT increase O‚ÇÇ consumption like Œ≤-agonists.',
                indications: 'Advanced heart failure refractory to dobutamine, right ventricular failure, pulmonary hypertension with RV dysfunction, post-cardiac surgery low CO, decompensated heart failure, cardiogenic shock.',
                contraindications: 'Severe aortic/pulmonary stenosis, hypovolemia, severe hypotension. Caution in renal failure (accumulation).',
                sideeffects: 'Hypotension (vasodilation), arrhythmias (especially ventricular), thrombocytopenia, headache, hypokalemia. May increase mortality in chronic use.',
                remarks: 'INODILATOR - both inotrope and vasodilator. EXCELLENT for RV failure and pulmonary hypertension. Does NOT work via adrenergic receptors - effective even with Œ≤-blocker use. Long half-life (2-3h) - effects persist after stopping. LOADING DOSE often omitted to avoid hypotension. Useful when dobutamine causes excessive tachycardia. May worsen hypotension - often combined with norepinephrine. Prolonged use associated with increased mortality in chronic HF trials.'
            },
            levosimendan: {
                category: 'Inotrope<br>Ca-sensitizer',
                name: 'Levosimendan',
                symbol: 'Levo',
                receptor: 'Ca++',
                dose: 'Adult: Load 6-12 Œºg/kg, then 0.05-0.2 Œºg/kg/min<br>Peds: 0.05-0.2 Œºg/kg/min',
                class: 'levosimendan',
                mechanism: 'Calcium sensitizer - increases troponin C sensitivity to Ca¬≤‚Å∫ WITHOUT increasing intracellular calcium. Also opens ATP-dependent K‚Å∫ channels ‚Üí vasodilation. Does NOT increase myocardial O‚ÇÇ consumption. Active metabolites last 7-9 days.',
                indications: 'Acute decompensated heart failure, cardiogenic shock, post-cardiac surgery low CO, septic cardiomyopathy. NOT available in USA.',
                contraindications: 'Severe hypotension (SBP <90), severe tachycardia, mechanical obstruction (HOCM, severe stenosis), severe renal/hepatic impairment.',
                sideeffects: 'Hypotension (common), tachycardia, arrhythmias, headache, hypokalemia. Hypotension may require vasopressor support.',
                remarks: 'UNIQUE mechanism - calcium sensitization. Very long duration due to active metabolites (OR-1896). Does NOT increase O‚ÇÇ consumption (unlike catecholamines) - safer in ischemic hearts. Often requires norepinephrine co-administration for hypotension. LOADING DOSE often omitted or reduced to minimize hypotension. May improve outcomes vs dobutamine in some studies. NOT FDA approved in USA. Preferred in cardiac surgery in some European centers.'
            },
            digoxin: {
                category: 'Inotrope<br>Cardiac glycoside',
                name: 'Digoxin',
                symbol: 'Dig',
                receptor: 'Na/K',
                dose: 'Adult: Load 0.5-1 mg, Maint 0.125-0.25 mg/day<br>Peds: Load 15-30 Œºg/kg, Maint 5-10 Œºg/kg/day',
                class: 'digoxin',
                mechanism: 'Na‚Å∫/K‚Å∫-ATPase inhibitor ‚Üí increased intracellular Ca¬≤‚Å∫ ‚Üí positive inotropy. Vagal effects: slows AV conduction, negative chronotropy. Positive inotropy + negative chronotropy.',
                indications: 'Atrial fibrillation with rapid ventricular response (rate control), chronic heart failure with reduced EF, supraventricular tachycardias.',
                contraindications: 'Ventricular fibrillation, AV block (2nd/3rd degree without pacemaker), WPW with AF, hypertrophic cardiomyopathy, acute MI.',
                sideeffects: 'Arrhythmias (ANY type possible), AV block, bradycardia, nausea, visual changes (yellow/green halos), confusion, hyperkalemia in toxicity.',
                remarks: 'NARROW therapeutic window (0.5-2 ng/mL). MANY drug interactions. Toxicity risk increased by hypokalemia, hypomagnesemia, hypercalcemia, renal failure. Does NOT reduce mortality in HF - only symptomatic benefit. Primarily used for rate control in AF. Toxicity can cause ANY arrhythmia. Monitor levels, renal function, electrolytes. DigiFab for severe toxicity.'
            },
            isoproterenol: {
                category: 'Inotrope<br>Pure Œ≤-agonist',
                name: 'Isoproterenol',
                symbol: 'Iso',
                receptor: 'Œ≤1, Œ≤2',
                dose: 'Adult: 0.5-10 Œºg/min<br>Peds: 0.05-0.5 Œºg/kg/min',
                class: 'isoproterenol',
                mechanism: 'Pure Œ≤1 and Œ≤2 agonist (NO Œ± activity). Powerful chronotrope and inotrope. Decreases SVR (Œ≤2). Increases HR, contractility, and CO. Profound vasodilation.',
                indications: 'Refractory bradycardia (bridge to pacing), torsades de pointes, Œ≤-blocker/calcium channel blocker overdose, temporary support for heart transplant denervated heart.',
                contraindications: 'Tachyarrhythmias, coronary insufficiency, digitalis toxicity.',
                sideeffects: 'Severe tachycardia, arrhythmias, myocardial ischemia, hypotension (vasodilation), increased myocardial O‚ÇÇ demand.',
                remarks: 'RARELY used - very arrhythmogenic. Massive increase in myocardial O‚ÇÇ consumption. May cause severe hypotension due to vasodilation despite increased CO. Useful for bradycardia when pacing not immediately available. Historical use in heart transplant patients (denervated hearts). AVOID in ischemic heart disease.'
            },
            metoprolol: {
                category: 'Œ≤-blocker<br>Œ≤1-selective',
                name: 'Metoprolol',
                symbol: 'Meto',
                receptor: 'Œ≤1',
                dose: 'Adult IV: 2.5-5 mg q5min (max 15mg)<br>PO: 25-200 mg BID<br>Peds: 1-2 mg/kg/day',
                class: 'metoprolol',
                mechanism: 'Cardioselective Œ≤1-blocker (Œ≤1 >> Œ≤2). Decreases HR, contractility, AV conduction, myocardial O‚ÇÇ demand. Reduces renin release. Membrane stabilizing effect at high doses.',
                indications: 'Acute coronary syndrome, hypertension, atrial fibrillation (rate control), heart failure (chronic - not acute), post-MI, hypertrophic cardiomyopathy, aortic dissection.',
                contraindications: 'Decompensated heart failure, cardiogenic shock, severe bradycardia, 2nd/3rd degree AV block, sick sinus syndrome, severe asthma/COPD, acute cocaine intoxication.',
                sideeffects: 'Bradycardia, hypotension, bronchospasm, fatigue, depression, masking of hypoglycemia, worsening heart failure, cold extremities.',
                remarks: 'CARDIOSELECTIVE (Œ≤1) but loses selectivity at higher doses. Two formulations: tartrate (IR, BID) and succinate (XL, daily). Mortality benefit in chronic heart failure (MERIT-HF trial). Start LOW dose in HF and titrate slowly. May worsen acute decompensated HF - NOT for acute use. Use cautiously in cocaine-associated chest pain (Œ±-mediated vasoconstriction).'
            },
            esmolol: {
                category: 'Œ≤-blocker<br>Ultra-short acting',
                name: 'Esmolol',
                symbol: 'Esmo',
                receptor: 'Œ≤1',
                dose: 'Adult: Load 500 Œºg/kg, then 50-300 Œºg/kg/min<br>Peds: 100-500 Œºg/kg/min',
                class: 'esmolol',
                mechanism: 'Ultra-short acting cardioselective Œ≤1-blocker. Rapid onset (1-2 min), very short half-life (9 min). Decreases HR and contractility. Metabolized by RBC esterases.',
                indications: 'Perioperative tachycardia/hypertension, supraventricular tachycardia, atrial fibrillation with RVR, acute aortic dissection, thyroid storm, critically ill patients needing titratable Œ≤-blockade.',
                contraindications: 'Same as other Œ≤-blockers: decompensated HF, cardiogenic shock, severe bradycardia, AV block, severe asthma.',
                sideeffects: 'Hypotension (most common), bradycardia, bronchospasm, heart failure exacerbation. Effects resolve quickly after stopping.',
                remarks: 'IDEAL for acute situations requiring rapid titration and reversibility. Very short half-life allows safe titration - effects dissipate within 10-20 min of stopping. Excellent for perioperative use. INFUSION only - not for bolus. Can transition to longer-acting Œ≤-blocker once stable. Useful when unsure if patient will tolerate Œ≤-blockade.'
            },
            propranolol: {
                category: 'Œ≤-blocker<br>Non-selective',
                name: 'Propranolol',
                symbol: 'Prop',
                receptor: 'Œ≤1, Œ≤2',
                dose: 'Adult IV: 0.5-1 mg slow push<br>PO: 10-320 mg/day<br>Peds: 0.5-1 mg/kg/day',
                class: 'propranolol',
                mechanism: 'Non-selective Œ≤-blocker (Œ≤1 and Œ≤2). Membrane stabilizing activity. Decreases HR, contractility, myocardial O‚ÇÇ demand. No intrinsic sympathomimetic activity.',
                indications: 'Hypertension, angina, post-MI, arrhythmias, hypertrophic cardiomyopathy, thyrotoxicosis, essential tremor, migraine prophylaxis, portal hypertension.',
                contraindications: 'Asthma/COPD (Œ≤2 blockade), decompensated HF, bradycardia, AV block, cardiogenic shock, cocaine use.',
                sideeffects: 'Bronchospasm (Œ≤2 blockade), bradycardia, hypotension, fatigue, depression, impotence, hypoglycemia masking, worsening peripheral vascular disease.',
                remarks: 'NON-SELECTIVE - blocks both Œ≤1 and Œ≤2. AVOID in asthma/COPD due to Œ≤2 blockade causing bronchoconstriction. Lipophilic - crosses blood-brain barrier (CNS effects: nightmares, depression). Used for portal hypertension in cirrhosis. NOT preferred for chronic HF (non-selective). Good for thyroid storm (blocks peripheral T4‚ÜíT3 conversion).'
            },
            carvedilol: {
                category: 'Œ≤-blocker<br>Œ±/Œ≤ blocker',
                name: 'Carvedilol',
                symbol: 'Carv',
                receptor: 'Œ≤, Œ±1',
                dose: 'Adult: 3.125-25 mg BID<br>Peds: 0.05-0.4 mg/kg BID',
                class: 'carvedilol',
                mechanism: 'Non-selective Œ≤-blocker + Œ±1-blocker. Vasodilation (Œ±1 blockade) + decreased HR/contractility (Œ≤ blockade). Antioxidant properties. Reduces afterload and preload.',
                indications: 'Chronic heart failure with reduced EF, post-MI LV dysfunction, hypertension.',
                contraindications: 'Decompensated HF, cardiogenic shock, severe bradycardia, AV block, severe hepatic impairment, asthma.',
                sideeffects: 'Hypotension (Œ± blockade), dizziness, bradycardia, fatigue, worsening HF initially, bronchospasm, hyperglycemia.',
                remarks: 'ONLY Œ≤-blocker with proven mortality benefit in HF with Œ±-blocking activity. Vasodilation from Œ±1 blockade helps offset increased afterload from Œ≤ blockade. Start VERY LOW and titrate slowly in HF (3.125 mg BID ‚Üí target 25-50 mg BID). May worsen HF initially - warn patients. Take with food to slow absorption and reduce orthostatic hypotension. Superior to metoprolol in some HF trials.'
            },
            labetalol: {
                category: 'Œ≤-blocker<br>Œ±/Œ≤ blocker',
                name: 'Labetalol',
                symbol: 'Labet',
                receptor: 'Œ≤, Œ±1',
                dose: 'Adult IV: 10-20 mg bolus, then 0.5-2 mg/min<br>PO: 100-400 mg BID<br>Peds: 0.2-1 mg/kg/dose',
                class: 'labetalol',
                mechanism: 'Combined Œ±1 and non-selective Œ≤-blocker (Œ≤:Œ± ratio 7:1 IV, 3:1 PO). Decreases BP via vasodilation (Œ±) and decreased CO (Œ≤). Maintains cerebral/renal blood flow.',
                indications: 'Hypertensive emergency, acute aortic dissection, preeclampsia/eclampsia, perioperative hypertension, pheochromocytoma (after Œ±-blockade).',
                contraindications: 'Asthma/COPD, decompensated HF, bradycardia, AV block, cardiogenic shock, severe hepatic disease.',
                sideeffects: 'Hypotension, bradycardia, bronchospasm, dizziness, nausea, scalp tingling, hepatotoxicity (rare).',
                remarks: 'EXCELLENT for hypertensive emergencies - rapid BP reduction without excessive decrease in cerebral perfusion. SAFE in pregnancy (preeclampsia/eclampsia). Slower onset than nicardipine but more predictable. Bronchospasm risk lower than pure Œ≤-blockers but still present. Useful in aortic dissection (reduces dP/dt). Can be given as repeated boluses or infusion.'
            },
            bisoprolol: {
                category: 'Œ≤-blocker<br>Œ≤1-selective',
                name: 'Bisoprolol',
                symbol: 'Biso',
                receptor: 'Œ≤1',
                dose: 'Adult: 1.25-10 mg daily<br>Peds: Limited data',
                class: 'bisoprolol',
                mechanism: 'Highly cardioselective Œ≤1-blocker. Long half-life (10-12h). No intrinsic sympathomimetic activity. Minimal lipophilicity (less CNS effects).',
                indications: 'Chronic heart failure with reduced EF, hypertension, angina, post-MI.',
                contraindications: 'Decompensated HF, cardiogenic shock, severe bradycardia, AV block, sick sinus syndrome.',
                sideeffects: 'Bradycardia, hypotension, fatigue, dizziness, worsening HF initially.',
                remarks: 'HIGHLY Œ≤1-selective - better tolerated in mild COPD than non-selective agents. Mortality benefit in HF (CIBIS-II trial). Once daily dosing. Start low (1.25 mg) in HF and titrate to target 10 mg. Hydrophilic - minimal CNS effects (less depression/nightmares than propranolol). Eliminated 50% renal/50% hepatic.'
            },
            nitroglycerin: {
                category: 'Vasodilator<br>Nitrate',
                name: 'Nitroglycerin',
                symbol: 'NTG',
                receptor: 'NO',
                dose: 'Adult: 5-200 Œºg/min IV<br>SL: 0.3-0.6 mg<br>Peds: 0.25-5 Œºg/kg/min',
                class: 'nitroglycerin',
                mechanism: 'NO donor ‚Üí smooth muscle relaxation. Primarily venodilator at low doses (decreases preload), arteriolar dilator at high doses (decreases afterload). Dilates coronary arteries. Decreases myocardial O‚ÇÇ demand.',
                indications: 'Acute coronary syndrome, acute pulmonary edema, hypertensive emergency, heart failure, coronary vasospasm (Prinzmetal angina).',
                contraindications: 'Hypotension (SBP <90), RV infarction, severe aortic stenosis, increased ICP, recent PDE-5 inhibitor use (sildenafil, tadalafil - within 24-48h).',
                sideeffects: 'Hypotension, reflex tachycardia, headache, methemoglobinemia (high doses), tolerance (develops rapidly), syncope.',
                remarks: 'VENODILATOR at low doses (reduces preload) ‚Üí good for pulmonary edema. AVOID in RV infarction (preload-dependent). Tolerance develops within 24-48h of continuous use - nitrate-free intervals needed. DANGEROUS interaction with PDE-5 inhibitors (Viagra) - can cause severe hypotension. Requires special non-PVC tubing. Use glass bottles. Headache very common (cerebral vasodilation).'
            },
            nitroprusside: {
                category: 'Vasodilator<br>Nitrate',
                name: 'Nitroprusside',
                symbol: 'NTP',
                receptor: 'NO',
                dose: 'Adult: 0.25-10 Œºg/kg/min<br>Peds: 0.5-8 Œºg/kg/min',
                class: 'nitroprusside',
                mechanism: 'Direct NO donor ‚Üí smooth muscle relaxation. Balanced arterial AND venous dilation (afterload + preload reduction). Immediate onset, ultra-short duration. Metabolized to cyanide then thiocyanate.',
                indications: 'Hypertensive emergency, acute aortic dissection (with Œ≤-blocker), acute heart failure, controlled hypotension during surgery, acute mitral/aortic regurgitation.',
                contraindications: 'Compensatory hypertension (aortic coarctation, AV shunt), severe renal/hepatic impairment, Leber optic atrophy, tobacco amblyopia, vitamin B12 deficiency.',
                sideeffects: 'Hypotension, cyanide toxicity (prolonged use >48h, high doses, renal failure), thiocyanate toxicity, increased ICP, methemoglobinemia, reflex tachycardia.',
                remarks: 'MOST POTENT vasodilator - immediate onset and offset. Risk of CYANIDE TOXICITY with prolonged use (>48-72h) or high doses (>2 Œºg/kg/min). Monitor thiocyanate levels if >48h use. Signs of toxicity: metabolic acidosis, altered mental status, seizures. Treatment: sodium thiosulfate, hydroxocobalamin. Light-sensitive - protect from light. MUST use with Œ≤-blocker in aortic dissection (prevents reflex tachycardia and increased dP/dt).'
            },
            hydralazine: {
                category: 'Vasodilator<br>Arteriolar dilator',
                name: 'Hydralazine',
                symbol: 'Hydra',
                receptor: 'Direct',
                dose: 'Adult IV: 10-20 mg q4-6h<br>PO: 25-100 mg QID<br>Peds: 0.1-0.2 mg/kg/dose IV',
                class: 'hydralazine',
                mechanism: 'Direct arteriolar vasodilator (afterload reduction). Mechanism unclear - possibly K‚Å∫ channel opening, decreased Ca¬≤‚Å∫ release. Causes reflex tachycardia and increased CO. No venodilation.',
                indications: 'Hypertensive emergency (especially pregnancy), heart failure (with nitrates - BiDil), hypertension, aortic/mitral regurgitation.',
                contraindications: 'Coronary artery disease (reflex tachycardia), mitral valve disease with tachycardia, dissecting aortic aneurysm.',
                sideeffects: 'Reflex tachycardia, headache, flushing, fluid retention, lupus-like syndrome (chronic use >200 mg/day), angina, hypotension.',
                remarks: 'SAFE in pregnancy (first-line for preeclampsia/eclampsia). Causes significant reflex tachycardia - may worsen angina. Used with nitrates in HF (especially in African Americans - A-HeFT trial). Drug-induced lupus with chronic high-dose use (>200 mg/day) - reversible. Often combined with Œ≤-blocker to prevent tachycardia.'
            },
            nicardipine: {
                category: 'Vasodilator<br>CCB - DHP',
                name: 'Nicardipine',
                symbol: 'Nicar',
                receptor: 'Ca++',
                dose: 'Adult: 5-15 mg/h IV<br>Peds: 0.5-3 Œºg/kg/min',
                class: 'nicardipine',
                mechanism: 'Dihydropyridine calcium channel blocker. Blocks L-type Ca¬≤‚Å∫ channels in vascular smooth muscle ‚Üí arterial vasodilation. Minimal cardiac effects (vascular selective). Cerebral vasodilator.',
                indications: 'Hypertensive emergency, perioperative hypertension, subarachnoid hemorrhage (prevent vasospasm), acute ischemic stroke with severe hypertension.',
                contraindications: 'Advanced aortic stenosis, acute MI, severe hypotension.',
                sideeffects: 'Hypotension, reflex tachycardia, headache, flushing, peripheral edema, phlebitis (peripheral IV).',
                remarks: 'EXCELLENT for acute BP control - predictable, titratable. PREFERRED over nitroprusside (no cyanide toxicity). Cerebral vasodilator - may increase ICP but maintains cerebral perfusion. SAFE in pregnancy. Reflex tachycardia less than hydralazine. Can cause phlebitis - central line preferred. Does NOT worsen coronary steal (unlike older CCBs).'
            },
            enalapril: {
                category: 'ACE Inhibitor<br>Prodrug',
                name: 'Enalapril',
                symbol: 'Enal',
                receptor: 'ACEi',
                dose: 'Adult IV: 0.625-1.25 mg q6h<br>PO: 2.5-40 mg daily<br>Peds: 0.05-0.1 mg/kg/day',
                class: 'enalapril',
                mechanism: 'ACE inhibitor - blocks conversion of angiotensin I ‚Üí II. Decreases SVR, aldosterone, sympathetic activity. Increases bradykinin (cough). Reduces afterload and preload.',
                indications: 'Heart failure, hypertension, post-MI LV dysfunction, diabetic nephropathy, chronic kidney disease.',
                contraindications: 'Pregnancy (teratogenic), bilateral renal artery stenosis, angioedema history, hyperkalemia.',
                sideeffects: 'Hypotension (especially first dose), hyperkalemia, acute kidney injury, cough (10-20%), angioedema (0.1-0.2%), rash.',
                remarks: 'Mortality benefit in HF and post-MI. First-dose hypotension common - start low. Monitor K‚Å∫ and creatinine. Cough due to bradykinin accumulation (switch to ARB if intolerable). AVOID in pregnancy (fetal renal dysgenesis). Risk of angioedema - more common in African Americans. Enalaprilat is IV form (only IV ACE inhibitor available).'
            },
            lisinopril: {
                category: 'ACE Inhibitor<br>Active form',
                name: 'Lisinopril',
                symbol: 'Lisin',
                receptor: 'ACEi',
                dose: 'Adult: 2.5-40 mg daily<br>Peds: 0.07-0.6 mg/kg/day',
                class: 'lisinopril',
                mechanism: 'ACE inhibitor - active form (not prodrug). Blocks angiotensin I ‚Üí II conversion. Long half-life allows once-daily dosing. Hydrophilic - minimal CNS penetration.',
                indications: 'Heart failure, hypertension, post-MI, diabetic nephropathy, chronic kidney disease.',
                contraindications: 'Pregnancy, bilateral RAS, angioedema history, hyperkalemia.',
                sideeffects: 'Hypotension, hyperkalemia, AKI, cough, angioedema, dizziness.',
                remarks: 'NOT a prodrug - active form. Once daily dosing. Hydrophilic - eliminated unchanged by kidneys (dose adjust in renal impairment). NO IV formulation. Same benefits as other ACE inhibitors. Start low in HF (2.5 mg) and titrate to target dose (20-40 mg).'
            },
            ramipril: {
                category: 'ACE Inhibitor<br>Prodrug',
                name: 'Ramipril',
                symbol: 'Rami',
                receptor: 'ACEi',
                dose: 'Adult: 1.25-10 mg daily<br>Peds: Limited data',
                class: 'ramipril',
                mechanism: 'ACE inhibitor prodrug ‚Üí ramiprilat (active). Long-acting. Tissue ACE inhibition. Reduces cardiovascular events.',
                indications: 'Heart failure, post-MI, hypertension, high CV risk (HOPE trial), diabetic nephropathy.',
                contraindications: 'Pregnancy, bilateral RAS, angioedema history.',
                sideeffects: 'Hypotension, hyperkalemia, AKI, cough, angioedema.',
                remarks: 'Proven CV risk reduction in HOPE trial. High tissue penetration. Once daily dosing. Prodrug - converted to active ramiprilat. Similar efficacy to other ACE inhibitors for HF and post-MI.'
            },
            amiodarone: {
                category: 'Antiarrhythmic<br>Class III',
                name: 'Amiodarone',
                symbol: 'Amio',
                receptor: 'K+',
                dose: 'Adult Load: 150 mg IV over 10min, then 1 mg/min √ó 6h, then 0.5 mg/min<br>PO: 400-800 mg/day √ó 1-3wk, then 200-400 mg/day<br>Peds: 5 mg/kg IV',
                class: 'amiodarone',
                mechanism: 'Class III antiarrhythmic - primarily K‚Å∫ channel blocker (prolongs repolarization/QT). Also blocks Na‚Å∫, Ca¬≤‚Å∫ channels, Œ±/Œ≤ receptors. Multiple mechanisms. Non-competitive Œ≤-blocker effect.',
                indications: 'Ventricular tachycardia/fibrillation, atrial fibrillation (rate/rhythm control), cardiac arrest (VF/pVT), SVT refractory to other agents.',
                contraindications: 'Sinus bradycardia, 2nd/3rd degree AV block (without pacemaker), long QT syndrome, iodine allergy (relative).',
                sideeffects: 'QT prolongation, torsades, bradycardia, hypotension (IV), pulmonary toxicity, hepatotoxicity, thyroid dysfunction (hypo/hyper), corneal deposits, photosensitivity, blue-gray skin discoloration.',
                remarks: 'MOST EFFECTIVE antiarrhythmic but MOST TOXIC. IV causes hypotension (due to solvent polysorbate 80). Use central line for prolonged infusion (causes phlebitis). Very long half-life (20-100 days) - effects persist weeks after stopping. Pulmonary toxicity most serious (interstitial pneumonitis/fibrosis) - monitor PFTs, CXR. Check thyroid function (contains iodine - 37% by weight). MANY drug interactions (CYP450 inhibitor). Reduces defibrillation threshold. Preferred in cardiac arrest and structural heart disease.'
            },
            lidocaine: {
                category: 'Antiarrhythmic<br>Class IB',
                name: 'Lidocaine',
                symbol: 'Lido',
                receptor: 'Na+',
                dose: 'Adult: 1-1.5 mg/kg bolus, then 1-4 mg/min<br>Peds: 1 mg/kg bolus, then 20-50 Œºg/kg/min',
                class: 'lidocaine',
                mechanism: 'Class IB antiarrhythmic - Na‚Å∫ channel blocker. Shortens action potential duration. Decreases ventricular automaticity. Minimal effect on atrial tissue.',
                indications: 'Ventricular arrhythmias (VT/VF), especially in acute MI, cardiac arrest (alternative to amiodarone), local anesthesia.',
                contraindications: 'Advanced AV block, severe sinus node dysfunction, Wolff-Parkinson-White syndrome, lidocaine allergy.',
                sideeffects: 'CNS toxicity (paresthesias, confusion, seizures), bradycardia, hypotension, heart block, methemoglobinemia.',
                remarks: 'VENTRICULAR-selective (minimal atrial effects). CNS toxicity dose-related: paresthesias ‚Üí drowsiness ‚Üí seizures ‚Üí coma. Reduce dose in liver disease, HF, elderly (decreased clearance). Monitor levels (therapeutic 1.5-5 Œºg/mL). Amiodarone now preferred over lidocaine in cardiac arrest. Good for VT in acute MI. NO longer recommended for routine prophylaxis post-MI.'
            },
            adenosine: {
                category: 'Antiarrhythmic<br>Nucleoside',
                name: 'Adenosine',
                symbol: 'Adeno',
                receptor: 'A1',
                dose: 'Adult: 6 mg rapid IV push, then 12 mg √ó 2 if needed<br>Peds: 0.1 mg/kg, max 6 mg initial',
                class: 'adenosine',
                mechanism: 'Activates A1 receptors ‚Üí increases K‚Å∫ conductance ‚Üí hyperpolarization. Slows AV conduction. Ultra-short half-life (<10 sec). Causes transient AV block.',
                indications: 'Supraventricular tachycardia (AVNRT, AVRT), wide-complex tachycardia (diagnostic), stress testing (pharmacologic).',
                contraindications: 'Asthma/COPD (bronchospasm), 2nd/3rd degree AV block, sick sinus syndrome, atrial fibrillation/flutter with WPW, recent dipyridamole use.',
                sideeffects: 'Transient asystole, flushing, chest pain/tightness, dyspnea, bronchospasm, sense of "impending doom".',
                remarks: 'ULTRA-SHORT half-life - effects last seconds. Give RAPID IV push followed by saline flush - use large bore IV, as proximal as possible. WARN patient of impending discomfort (chest pain, flushing, dyspnea). Causes brief asystole - have defibrillator ready. May unmask WPW pattern. Bronchospasm risk - avoid in asthma. Caffeine/theophylline antagonize effects (higher doses needed). Dipyridamole potentiates effects (contraindicated within 24h). NOT effective for atrial fib/flutter (may cause transient AV block revealing flutter waves). Record ECG during administration.'
            },
            procainamide: {
                category: 'Antiarrhythmic<br>Class IA',
                name: 'Procainamide',
                symbol: 'Proc',
                receptor: 'Na+',
                dose: 'Adult: 15-18 mg/kg IV over 30-60min, then 1-4 mg/min<br>Peds: 15 mg/kg IV load',
                class: 'procainamide',
                mechanism: 'Class IA - Na‚Å∫ channel blocker + K‚Å∫ channel blocker. Slows conduction, prolongs repolarization. Active metabolite NAPA also antiarrhythmic.',
                indications: 'Ventricular tachycardia, atrial fibrillation (especially with WPW), SVT, pre-excitation syndromes.',
                contraindications: 'Torsades de pointes, long QT, SLE, complete AV block, myasthenia gravis.',
                sideeffects: 'Hypotension, QT prolongation, torsades, drug-induced lupus (50-90% with chronic use), agranulocytosis, heart block, QRS widening.',
                remarks: 'RARELY used chronically due to lupus (50-90% develop lupus antibodies). Monitor BP during infusion (can cause severe hypotension - slow infusion). Watch QRS width (stop if >50% increase) and QT interval. Check ANA levels periodically. Good for WPW with AF (amiodarone may paradoxically increase conduction through accessory pathway). NAPA metabolite accumulates in renal failure.'
            },
            sotalol: {
                category: 'Antiarrhythmic<br>Class III + Œ≤-blocker',
                name: 'Sotalol',
                symbol: 'Sota',
                receptor: 'K+, Œ≤',
                dose: 'Adult: 80-160 mg BID PO<br>Peds: 30-90 mg/m¬≤/dose',
                class: 'sotalol',
                mechanism: 'Dual mechanism: Class III (K‚Å∫ channel blocker - prolongs QT) + non-selective Œ≤-blocker. Prolongs repolarization and decreases HR.',
                indications: 'Ventricular arrhythmias, atrial fibrillation (rhythm control), life-threatening arrhythmias.',
                contraindications: 'Long QT syndrome, torsades, severe renal impairment (accumulates), asthma, bradycardia, decompensated HF, hypokalemia.',
                sideeffects: 'Torsades de pointes (dose-related), bradycardia, heart failure, bronchospasm, fatigue, QT prolongation.',
                remarks: 'PROARRHYTHMIC - torsades risk 2-4% (dose-dependent). MUST initiate in hospital with continuous monitoring (first 3 days). Check QTc before each dose increase - hold if QTc >500 ms. Renally excreted - dose adjust for CrCl. Correct hypokalemia before starting. More effective than other antiarrhythmics but higher torsades risk. Combines benefits of Œ≤-blocker and Class III agent.'
            },
            furosemide: {
                category: 'Diuretic<br>Loop diuretic',
                name: 'Furosemide',
                symbol: 'Lasix',
                receptor: 'Na/K/2Cl',
                dose: 'Adult: 20-80 mg IV/PO, max 600 mg/day<br>Infusion: 5-40 mg/h<br>Peds: 0.5-2 mg/kg/dose',
                class: 'furosemide',
                mechanism: 'Loop diuretic - inhibits Na‚Å∫-K‚Å∫-2Cl‚Åª cotransporter in thick ascending limb of Henle. Venodilation (rapid - before diuresis). Decreases preload, pulmonary congestion.',
                indications: 'Acute pulmonary edema, heart failure exacerbation, volume overload, hypertension, hypercalcemia, acute kidney injury (controversial).',
                contraindications: 'Anuria, severe electrolyte depletion, hepatic coma, sulfa allergy.',
                sideeffects: 'Hypokalemia, hypomagnesemia, hypocalcemia, metabolic alkalosis, ototoxicity (high doses), hyperuricemia, hyperglycemia, hypovolemia, hyponatremia.',
                remarks: 'MOST commonly used loop diuretic. IV administration causes immediate venodilation (reduces preload before diuresis starts). Ceiling effect - doubling dose doesn\'t double response; use continuous infusion if resistant. Ototoxicity with high doses/rapid infusion - risk with aminoglycosides. Monitor electrolytes (especially K‚Å∫, Mg¬≤‚Å∫). Poor absorption in gut edema - IV preferred in acute HF. May need to add thiazide (metolazone) for diuretic resistance. AVOID in hypovolemic states.'
            },
            bumetanide: {
                category: 'Diuretic<br>Loop diuretic',
                name: 'Bumetanide',
                symbol: 'Bumex',
                receptor: 'Na/K/2Cl',
                dose: 'Adult: 0.5-2 mg IV/PO<br>Peds: 0.015-0.1 mg/kg/dose',
                class: 'bumetanide',
                mechanism: 'Loop diuretic - Na‚Å∫-K‚Å∫-2Cl‚Åª cotransporter inhibitor. More potent than furosemide (40:1 ratio). Better bioavailability.',
                indications: 'Heart failure, edema, furosemide resistance, hypertension.',
                contraindications: 'Anuria, severe electrolyte depletion, sulfa allergy, hepatic coma.',
                sideeffects: 'Similar to furosemide: hypokalemia, metabolic alkalosis, ototoxicity (less than furosemide), hyperuricemia.',
                remarks: '40√ó more potent than furosemide (1 mg bumetanide ‚âà 40 mg furosemide). Better oral bioavailability (80-90% vs 50% for furosemide) - more reliable PO dosing. LESS ototoxic than furosemide. Useful when switching from IV to PO due to predictable absorption. Shorter duration than furosemide. Consider when furosemide resistance develops.'
            },
            torsemide: {
                category: 'Diuretic<br>Loop diuretic',
                name: 'Torsemide',
                symbol: 'Torsem',
                receptor: 'Na/K/2Cl',
                dose: 'Adult: 10-20 mg IV/PO daily<br>Peds: Limited data',
                class: 'torsemide',
                mechanism: 'Loop diuretic - Na‚Å∫-K‚Å∫-2Cl‚Åª cotransporter inhibitor. Longer half-life (3-4h vs 1.5h for furosemide). Additional aldosterone antagonist effects.',
                indications: 'Heart failure (especially chronic), hypertension, edema, cirrhotic ascites.',
                contraindications: 'Anuria, severe electrolyte depletion, sulfa allergy.',
                sideeffects: 'Hypokalemia, metabolic alkalosis, hyperuricemia, ototoxicity (rare).',
                remarks: 'BEST oral bioavailability (80-90%) - reliable PO dosing. Longer duration allows once-daily dosing. May be superior to furosemide in chronic HF (TRANSFORM-HF trial - neutral results). Less ototoxic than furosemide. 1 mg torsemide ‚âà 2 mg bumetanide ‚âà 40 mg furosemide. Some aldosterone antagonist effect. Useful for chronic HF management.'
            },
            spironolactone: {
                category: 'Diuretic<br>K‚Å∫-sparing MRA',
                name: 'Spironolactone',
                symbol: 'Spir',
                receptor: 'MRA',
                dose: 'Adult: 12.5-50 mg daily<br>Peds: 1-3 mg/kg/day',
                class: 'spironolactone',
                mechanism: 'Mineralocorticoid receptor antagonist (MRA) - blocks aldosterone in distal tubule. Weak diuretic but potent mortality benefit in HF. Anti-fibrotic, anti-remodeling effects.',
                indications: 'Heart failure with reduced EF (mortality benefit), resistant hypertension, primary hyperaldosteronism, cirrhotic ascites.',
                contraindications: 'Hyperkalemia (K‚Å∫ >5.5), severe renal failure (CrCl <30), Addison disease, concurrent K‚Å∫-sparing diuretics.',
                sideeffects: 'Hyperkalemia (LIFE-THREATENING), gynecomastia (20% men), menstrual irregularities, GI upset, hyponatremia.',
                remarks: 'MORTALITY BENEFIT in HF (RALES trial - 30% mortality reduction). Start LOW dose (12.5-25 mg) and monitor K‚Å∫ closely (weekly √ó 1 month, then monthly). DANGEROUS hyperkalemia risk - avoid with K‚Å∫ >5, CrCl <30, or ACE-I/ARB + NSAIDs. Gynecomastia common (non-selective MRA) - switch to eplerenone if bothersome. Anti-fibrotic effects independent of diuresis. Essential in HF with EF <35%.'
            },
            eplerenone: {
                category: 'Diuretic<br>K‚Å∫-sparing MRA',
                name: 'Eplerenone',
                symbol: 'Epler',
                receptor: 'MRA',
                dose: 'Adult: 25-50 mg daily<br>Peds: Limited data',
                class: 'eplerenone',
                mechanism: 'Selective mineralocorticoid receptor antagonist. More selective than spironolactone (less anti-androgen effects). Blocks aldosterone, reduces cardiac fibrosis.',
                indications: 'Heart failure post-MI, HFrEF, hypertension.',
                contraindications: 'Hyperkalemia, severe renal impairment, concurrent strong CYP3A4 inhibitors.',
                sideeffects: 'Hyperkalemia, hyponatremia, dizziness. LESS gynecomastia than spironolactone.',
                remarks: 'SELECTIVE MRA - much less gynecomastia than spironolactone. Mortality benefit post-MI (EPHESUS trial). Monitor K‚Å∫ closely. More expensive than spironolactone. Preferred when gynecomastia is issue. CYP3A4 interactions - avoid with ketoconazole, itraconazole.'
            },
            heparin: {
                category: 'Anticoagulant<br>Unfractionated',
                name: 'Heparin (UFH)',
                symbol: 'UFH',
                receptor: 'ATIII',
                dose: 'Adult: 60-80 U/kg bolus, then 12-18 U/kg/h<br>Peds: 75 U/kg bolus, then 20 U/kg/h',
                class: 'heparin',
                mechanism: 'Binds antithrombin III ‚Üí inactivates thrombin (IIa) and factor Xa. Immediate anticoagulation. Monitored by aPTT (target 1.5-2.5√ó control).',
                indications: 'ACS, PE/DVT, atrial fibrillation, mechanical valves, ECMO/CVVH, cardiopulmonary bypass.',
                contraindications: 'Active bleeding, severe thrombocytopenia, HIT (heparin-induced thrombocytopenia).',
                sideeffects: 'Bleeding, HIT (0.1-5%), osteoporosis (long-term), hyperkalemia, alopecia.',
                remarks: 'IMMEDIATE anticoagulation - preferred when rapid reversal may be needed (protamine). Monitor aPTT (target 60-80 sec or 1.5-2.5√ó baseline). HIT risk - monitor platelets (especially days 5-14). Protamine reverses (1 mg per 100 U heparin). Preferred over LMWH in renal failure, extreme obesity, when rapid on/off needed (pre-procedure).'
            },
            enoxaparin: {
                category: 'Anticoagulant<br>LMWH',
                name: 'Enoxaparin',
                symbol: 'LMWH',
                receptor: 'Xa > IIa',
                dose: 'Adult: 1 mg/kg q12h or 1.5 mg/kg daily<br>Peds: 1 mg/kg q12h',
                class: 'enoxaparin',
                mechanism: 'Low molecular weight heparin - preferentially inhibits factor Xa > IIa. More predictable than UFH. Longer half-life.',
                indications: 'ACS, PE/DVT treatment/prophylaxis, bridging anticoagulation.',
                contraindications: 'Severe renal impairment (CrCl <30), active bleeding, HIT.',
                sideeffects: 'Bleeding, HIT (lower risk than UFH), spinal hematoma (avoid with neuraxial procedures), osteoporosis.',
                remarks: 'MORE predictable than UFH - usually no monitoring needed. Avoid in severe renal failure (accumulates - dose reduce if CrCl 30-50). LOWER HIT risk than UFH. Partially reversed by protamine (60-80%). Contraindicated within 12h of neuraxial anesthesia/catheter manipulation. Preferred over UFH for outpatient DVT/PE treatment.'
            },
            warfarin: {
                category: 'Anticoagulant<br>Vitamin K antagonist',
                name: 'Warfarin',
                symbol: 'Warf',
                receptor: 'Vit. K',
                dose: 'Adult: 2-10 mg daily (titrate to INR)<br>Peds: 0.1-0.3 mg/kg/day',
                class: 'warfarin',
                mechanism: 'Vitamin K antagonist - inhibits factors II, VII, IX, X and proteins C, S. Monitored by INR (target varies by indication: 2-3 for most, 2.5-3.5 for mechanical valves).',
                indications: 'Atrial fibrillation, mechanical heart valves, DVT/PE, left ventricular thrombus.',
                contraindications: 'Pregnancy (teratogenic), active bleeding, inability to monitor INR, recent CNS surgery.',
                sideeffects: 'Bleeding, skin necrosis (proteins C/S deficiency), warfarin-induced limb gangrene, teratogenicity.',
                remarks: 'NARROW therapeutic window - frequent INR monitoring required. MANY drug and food interactions. Teratogenic - avoid in pregnancy (especially 1st trimester). Bridging with heparin needed (initial paradoxical hypercoagulability from protein C/S inhibition). Reversed by vitamin K (slow, 6-24h) or PCC/FFP (immediate). DOACs replacing warfarin for many indications except mechanical valves.'
            },
            apixaban: {
                category: 'Anticoagulant<br>DOAC - Xa inhibitor',
                name: 'Apixaban',
                symbol: 'Apix',
                receptor: 'Xa-i',
                dose: 'Adult: 5 mg BID (AF), 2.5 mg BID if ‚â•2: age‚â•80, wt‚â§60kg, Cr‚â•1.5<br>DVT: 10 mg BID √ó 7d, then 5 mg BID',
                class: 'apixaban',
                mechanism: 'Direct oral anticoagulant (DOAC) - direct factor Xa inhibitor. Predictable pharmacokinetics. No routine monitoring needed.',
                indications: 'Atrial fibrillation (stroke prevention), DVT/PE treatment and prophylaxis.',
                contraindications: 'Active bleeding, severe hepatic impairment, mechanical valves, severe renal impairment (CrCl <15).',
                sideeffects: 'Bleeding (lower than warfarin), GI upset. No reversal agent widely available (andexanet alfa).',
                remarks: 'LOWEST bleeding risk among DOACs (especially intracranial). BID dosing (adherence concern). Dose reduce if ‚â•2 criteria: age‚â•80, weight‚â§60kg, Cr‚â•1.5. NO routine monitoring needed. Reversal: andexanet alfa (expensive, limited availability). Preferred over warfarin in many patients (ARISTOTLE trial). NOT for mechanical valves (increased thromboembolic events).'
            }
        };

        const table = document.getElementById('pharmaTable');
        const tooltip = document.getElementById('tooltip');

        // Define drug order
        const drugOrder = [
            // Row 1: Vasopressors
            'norepinephrine', 'epinephrine', 'vasopressin', 'phenylephrine', 'dopamine', 'terlipressin',
            // Row 2: Inotropes
            'dobutamine', 'milrinone', 'levosimendan', 'digoxin', 'isoproterenol',
            // Row 3: Beta-blockers (need one more to complete)
            'metoprolol', 'esmolol', 'propranolol', 'carvedilol', 'labetalol', 'bisoprolol',
            // Row 4: Vasodilators + ACE inhibitors
            'nitroglycerin', 'nitroprusside', 'hydralazine', 'nicardipine', 'enalapril', 'lisinopril',
            // Row 5: ACE + Antiarrhythmics
            'ramipril', 'amiodarone', 'lidocaine', 'adenosine', 'procainamide', 'sotalol',
            // Row 6: Diuretics + Anticoagulants
            'furosemide', 'bumetanide', 'torsemide', 'spironolactone', 'eplerenone', 'heparin',
            // Row 7: Anticoagulants
            'enoxaparin', 'warfarin', 'apixaban'
        ];

        drugOrder.forEach(drugId => {
            const drug = drugs[drugId];
            if (drug) {
                const element = document.createElement('div');
                element.className = `card ${drug.class}`;
                element.innerHTML = `
                    <div class="card-category">${drug.category}</div>
                    <div class="card-receptor">${drug.receptor || ''}</div>
                    <div class="card-name">${drug.symbol || drug.name}</div>
                    <div class="card-dose">${drug.dose}</div>
                `;
                
                element.addEventListener('mouseenter', (e) => showTooltip(e, drug));
                element.addEventListener('mousemove', (e) => updateTooltipPosition(e));
                element.addEventListener('mouseleave', hideTooltip);
                
                table.appendChild(element);
            }
        });

        function showTooltip(e, drug) {
            const color = window.getComputedStyle(e.currentTarget).color;
            const borderColor = window.getComputedStyle(e.currentTarget).borderColor;
            
            tooltip.style.color = color;
            tooltip.style.borderColor = borderColor;
            
            tooltip.innerHTML = `
                <div class="tooltip-title">${drug.name}</div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Mechanism of Action</div>
                    <div class="tooltip-section-content">${drug.mechanism}</div>
                </div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Indications</div>
                    <div class="tooltip-section-content">${drug.indications}</div>
                </div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Contraindications</div>
                    <div class="tooltip-section-content">${drug.contraindications}</div>
                </div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Side Effects</div>
                    <div class="tooltip-section-content">${drug.sideeffects}</div>
                </div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Clinical Pearls & Remarks</div>
                    <div class="tooltip-section-content">${drug.remarks}</div>
                </div>
            `;
            
            updateTooltipPosition(e);
            tooltip.classList.add('active');
        }

        function updateTooltipPosition(e) {
            const margin = 20;
            let x = e.clientX + margin;
            let y = e.clientY + margin;
            
            const tooltipRect = tooltip.getBoundingClientRect();
            
            if (x + tooltipRect.width > window.innerWidth - margin) {
                x = e.clientX - tooltipRect.width - margin;
            }
            
            if (y + tooltipRect.height > window.innerHeight - margin) {
                y = e.clientY - tooltipRect.height - margin;
            }
            
            tooltip.style.left = x + 'px';
            tooltip.style.top = y + 'px';
        }

        function hideTooltip() {
            tooltip.classList.remove('active');
        }
    </script>
    <script src="../JS/search.js"></script>
    <script src="../JS/main.js"></script>
</body>
</html>